Madrigal Pharmaceuticals, Inc. filings document the company’s biopharmaceutical business, commercial reporting for Rezdiffra (resmetirom), and governance matters tied to its Nasdaq-listed common stock. Current reports include quarterly results furnished under Item 2.02, updates on Rezdiffra net sales and cash resources, and Regulation FD disclosures related to pipeline and licensing activity in MASH.
Other filings cover material agreements affecting Rezdiffra intellectual property and royalties, including amendments to a research, development and commercialization agreement, as well as proxy disclosures for director classes, board matters, executive compensation and equity incentive plans. The filing record also documents stockholder meeting proposals and corporate-governance actions for a commercial-stage biopharmaceutical company developing metabolic liver-disease therapies.
Madrigal Pharmaceuticals, Inc. (MDGL) director Paul Friedman reported a proposed sale of 50,000 common shares, with an aggregate market value of $25,828,000 and an approximate sale date of September 28, 2026. The shares are listed as acquired from the issuer through exercise of stock options, with cash payment, on September 28, 2026. The sale is reported as occurring automatically under a Rule 10b5-1 trading plan Paul Friedman adopted on August 28, 2026.
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported that President and CEO William John Sibold sold 11,583 shares of common stock in 24 open-market transactions on September 9 and 11, 2026. Sales on September 9 were made by the issuer on his behalf to cover tax withholding from vesting restricted stock units, and were automatic. Sales on September 11 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted on June 5, 2026.
Madrigal Pharmaceuticals, Inc. (MDGL) received a Form 144 notice indicating that William Sibold plans to sell 5,221 shares of common stock through Morgan Stanley Smith Barney LLC on or after September 11, 2026, with an indicated aggregate market value of $2,783,419.52.
The shares relate to Restricted Stock Units acquired on September 8, 2025. The notice also reports prior sales in the last three months totaling 6,362 shares for $3,407,397.50 on September 9, 2026 and 2,500 shares for $1,368,253.45 on July 20, 2026, executed under a Rule 10b5-1 trading plan adopted on June 5, 2026.
Madrigal Pharmaceuticals, Inc. (MDGL) disclosed a Rule 144 notice indicating that officer and director William John Sibold plans to sell 6,362 shares of common stock through Morgan Stanley Smith Barney LLC. The shares relate to vested Restricted Stock Units, and a prior sale of 2,500 shares occurred on July 20, 2026. The company states the sale covers tax withholding obligations tied to RSU vesting and was automatic, not at Sibold’s discretion.
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported that officer Kelley T. Shannon, General Counsel, had 664 shares of common stock sold on 2026-08-17 at $514.97 per share. According to the company’s disclosure, the shares were sold by the issuer on her behalf solely to cover tax withholding obligations from vesting restricted stock units and were automatic, not at her discretion. Following this transaction, she directly holds 11,474 MDGL common shares.
Madrigal Pharmaceuticals, Inc. (MDGL) received a Rule 144 notice from officer Shannon Kelley covering a planned sale of 664 shares of common stock through Morgan Stanley Smith Barney LLC on the Nasdaq Stock Market. The shares relate to a Restricted Stock Unit grant acquired on 08/15/2026 and vesting on 08/17/2026.
The filing states that the sale represents a sell-to-cover transaction to satisfy tax withholding obligations arising from the RSU vesting, not a discretionary sale of additional shares.
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported equity compensation grants to director John C. Reed. He received 647 shares of Common Stock as restricted stock units that vest 50% on August 15, 2027 and 50% on August 15, 2028, subject to continued service. He also received a stock option for 1,078 shares at an exercise price of $507.56 per share, expiring August 15, 2036, vesting 50% on August 15, 2027 and 12.5% at the end of each successive three-month period for four periods thereafter, contingent on continued service.
MADRIGAL PHARMACEUTICALS, INC. (MDGL) filed an initial ownership report for John C. Reed, who is identified as a director of the company. This Form 3 does not list any stock or derivative holdings and reports no transactions. The filing also references an Exhibit 24 Power of Attorney authorizing filing actions.
Madrigal Pharmaceuticals, Inc. expanded its Board of Directors from eight to nine members and elected John C. Reed, M.D., Ph.D. as a Class II director effective August 11, 2026, with a term expiring at the 2027 annual meeting. He was appointed to the Board’s Science and Technology Committee. As a non-employee director, he will receive an annual cash retainer of $50,000 plus $10,000 annually for committee service, under Madrigal’s Non-Employee Director Compensation Policy. In connection with his appointment, he will receive an equity grant valued at $675,000, split equally between nonqualified stock options and restricted stock units under the 2026 Stock Plan, subject to multi-year vesting tied to continued service. Madrigal highlighted Dr. Reed’s current leadership role at Johnson & Johnson and his extensive biopharmaceutical and research background, and reiterated its focus on Rezdiffra, the first medication approved by the FDA and European Commission for MASH with fibrosis stages F2 to F3.
Madrigal Pharmaceuticals reported continued commercial ramp of Rezdiffra for MASH. Net product revenue reached $364.3 million in Q2 2026 and $675.6 million for the first half of 2026, up from $212.8 million and $350.1 million a year earlier, respectively. The company still posted a net loss of $57.9 million for Q2 and $152.3 million for the first half, driven by higher cost of sales, research and development, and selling, general and administrative expenses, including rising stock-based compensation.
At June 30, 2026, Madrigal held $838.9 million in cash, cash equivalents, restricted cash and marketable securities and carried a $350 million senior secured term loan bearing interest at 8.45%, with a covenant requiring at least $100 million of unrestricted cash. Management expects existing liquid resources to fund operations for more than one year. The company recorded a $10.4 million inventory write-down and continues to invest heavily in MASH pipeline expansion through large global licensing deals (CSPC, Pfizer, Ribocure, Arrowhead) while advancing the MAESTRO-NASH outcomes programs intended to support full approvals and broader Rezdiffra indications.